The FTC is not anti-direct selling. It’s pro-truth in advertising.
The DSA misses the mark.
In August 2012, a class action was brought on behalf of New Yorkers claiming, among other things, that the makers of pill, TA-65, which is marketed as an anti-aging supplement, “have failed to reasonably warn consumers of the potential dangerous consequences associated with TA-65 telomerase activation and malignant tumor formation.” (Egan, et al. v. Telomerase Activation Sciences, Inc. et al., Case No. 652533/2012, S.C.N.Y.)
The DSA misses the mark.
TINA.org reader takes issue with this product’s deceptive packaging.
Don’t let this company blindside you with its deceptive pricing.
Lawsuit pokes holes in company’s Swiss branding.
Why are these airport vendors slyly charging consumers for “employee benefits”?